✦ LIBER ✦

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

✍ Scribed by Tanaka, C; Yin, O Q P; Sethuraman, V; Smith, T; Wang, X; Grouss, K; Kantarjian, H; Giles, F; Ottmann, O G; Galitz, L

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Regulation of the c-Abl and Bcr–Abl Tyro

✍ Hantschel, Oliver; Superti-Furga, Giulio 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 602 KB

Effects of a selective inhibitor of the

✍ Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Sha 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 617 KB

Genomic instability: The cause and effec

✍ Tomasz Skorski 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 170 KB

Development of NS-187, a potent and sele

✍ Shinya Kimura; Tomoko Niwa; Kazuko Hirabayashi; Taira Maekawa 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 381 KB

The Bcr-Abl tyrosine kinase inhibitor im

✍ Taira Maekawa; Eishi Ashihara; Shinya Kimura 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 495 KB

Complexity of BCR-ABL kinase domain muta

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views